cohort study: With median follow-up time &gt; 8 years, semaglutide was associated with the lowest risk of hospitalization due to AUD in individuals with comorbid obesity/T2DM (aHR=0.64; 0.50-0.83) followed by liraglutide (0.72; 0.57-0.92)